(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

May 21, 2020

(Date
of Event which Requires Filing of this Statement)

If the filing
person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rules 13d-1(e),13d-1(f) or 13d-1(g), check the following box. ☐

CUSIP No. M47364100

1

NAME OF REPORTING PERSON.

AI Gamida Holdings LLC

2

CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS (SEE
INSTRUCTIONS)

AF

5

CHECK IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

Excludes 3,042,489 Ordinary Shares that are beneficially owned by Clal Biotechnology Industries Ltd. and its
subsidiaries and 3,111,111 Ordinary Shares that are directly owned by AI Biotechnology LLC.

(2)

All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement assume an
aggregate of 47,323,840 Ordinary Shares issued and outstanding on May 21, 2020, after giving effect to the Issuers public offering of Ordinary Shares, as described in the prospectus of the Issuer dated May 20, 2020.

CUSIP No. M47364100

1

NAME OF REPORTING PERSON.

Access Industries Holdings LLC

2

CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS (SEE
INSTRUCTIONS)

AF

5

CHECK IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement assume an
aggregate of 47,323,840 Ordinary Shares issued and outstanding on May 21, 2020, after giving effect to the Issuers public offering of Ordinary Shares, as described in the prospectus of the Issuer dated May 20, 2020.

CUSIP No. M47364100

1

NAME OF REPORTING PERSON.

Access Industries, LLC

2

CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS (SEE
INSTRUCTIONS)

AF

5

CHECK IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement assume an
aggregate of 47,323,840 Ordinary Shares issued and outstanding on May 21, 2020, after giving effect to the Issuers public offering of Ordinary Shares, as described in the prospectus of the Issuer dated May 20, 2020.

CUSIP No. M47364100

1

NAME OF REPORTING PERSON.

Access Industries Management, LLC

2

CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS (SEE
INSTRUCTIONS)

AF

5

CHECK IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement assume an
aggregate of 47,323,840 Ordinary Shares issued and outstanding on May 21, 2020, after giving effect to the Issuers public offering of Ordinary Shares, as described in the prospectus of the Issuer dated May 20, 2020.

CUSIP No. M47364100

1

NAME OF REPORTING PERSON.

Clal Biotechnology Industries Ltd.

2

CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS (SEE
INSTRUCTIONS)

WC

5

CHECK IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement assume an
aggregate of 47,323,840 Ordinary Shares issued and outstanding on May 21, 2020, after giving effect to the Issuers public offering of Ordinary Shares, as described in the prospectus of the Issuer dated May 20, 2020.

CUSIP No. M47364100

1

NAME OF REPORTING PERSON.

Bio Medical Investment (1997) Ltd.

2

CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS (SEE
INSTRUCTIONS)

WC

5

CHECK IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement assume an
aggregate of 47,323,840 Ordinary Shares issued and outstanding on May 21, 2020, after giving effect to the Issuers public offering of Ordinary Shares, as described in the prospectus of the Issuer dated May 20, 2020.

CUSIP No. M47364100

1

NAME OF REPORTING PERSON.

Len Blavatnik

2

CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS (SEE
INSTRUCTIONS)

AF

5

CHECK IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement assume an
aggregate of 47,323,840 Ordinary Shares issued and outstanding on May 21, 2020, after giving effect to the Issuers public offering of Ordinary Shares, as described in the prospectus of the Issuer dated May 20, 2020.

CUSIP No. M47364100

1

NAME OF REPORTING PERSON.

AI Biotechnology LLC

2

CHECK THE APPROPRIATE BOX
IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

(a) ☐ (b) ☐

3

SEC USE ONLY

4

SOURCE OF FUNDS (SEE
INSTRUCTIONS)

AF

5

CHECK IF DISCLOSURE OF
LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)

All percentages of ownership of the Ordinary Shares by Reporting Persons presented in this Statement assume an
aggregate of 47,323,840 Ordinary Shares issued and outstanding on May 21, 2020, after giving effect to the Issuers public offering of Ordinary Shares, as described in the prospectus of the Issuer dated May 20, 2020.

The Schedule 13D filed by the Original Reporting Persons with the Securities and Exchange Commission (the SEC) on November 9,
2018, as amended and supplemented by Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on July 3, 2019 (together, the Schedule), is hereby amended and supplemented by the Reporting Persons as set
forth below in this Amendment No. 2. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended, and refers only to information that
has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and
not defined herein have the respective meanings assigned to them in the Schedule.

Item 3

Source and Amount of Funds or Other Considerations

Item 3 to the Schedule is hereby amended by adding the following paragraph to the end of Item 3:

On May 21, 2020, AIB purchased 1,111,111 Ordinary Shares in the Issuers public offering at a price of $4.50 per share. AIB funded
this purchase using capital contributed from affiliated entities, which funded that capital using cash on hand.

Item 5

Interest in Securities of the Issuer

Item 5 to the Schedule is hereby amended and restated as follows:

(a) and (b) The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D
that relate to the aggregate number and percentage of common stock (including but not limited to footnotes to such information) are incorporated herein by reference.

The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the
number of common stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited
to footnotes to such information) are incorporated herein by reference.

3,750,000 Ordinary Shares are owned directly by AI Gamida and may
be deemed to be beneficially owned by AIM and Len Blavatnik because (i) AIM and Len Blavatnik control AI Gamida, and (ii) Len Blavatnik controls AIM. Each of the Reporting Persons (other than AI Gamida), and each of their affiliated
entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of the securities held directly by AI Gamida.

3,042,489 Ordinary Shares may be deemed to be beneficially owned by CBI, including (i) 1,507,369 Ordinary Shares owned directly by CBI, (ii)
160,743 Ordinary Shares issuable upon exercise of warrants owned directly by CBI and (iii) 1,374,377 Ordinary Shares owned directly by Bio Medical, which is a wholly owned subsidiary of CBI. CBI may be deemed to share voting and investment power
over the shares held directly by Bio Medical because it controls that entity. CBI is a publicly traded company traded on the Tel Aviv Stock Exchange.

1,374,377 Ordinary Shares are owned directly by Bio Medical, which is a wholly owned subsidiary of CBI.

3,111,111 Ordinary Shares are owned directly by AIB, which is a wholly owned subsidiary of AIH.

Each of AIH, Access LLC, AIM and Mr. Blavatnik may be deemed to share voting and
investment power over the Ordinary Shares deemed to be beneficially owned by CBI (including the shares held directly by Bio Medical) and the Ordinary Shares owned directly by AIB because (i) Len Blavatnik controls AIM, AIH, Access LLC and AI
International GP Limited (the general partner of AI SMS, as defined below), (ii) Access LLC controls a majority of the outstanding voting interests in AIH, (iii) AIM controls Access LLC and AIH, (iv) AIH owns AIB, (v) AIH owns a
majority of the equity of AI SMS L.P. (AI SMS), (vi) AI SMS owns a majority of the equity of AI Diversified Holdings Ltd. (Holdings Limited), (vii) Holdings Limited owns AI Diversified Parent S.à r.l., which owns AI
Diversified Holdings S.à r.l., which owns Access AI Ltd (Access AI), (viii) Access AI wholly owns Clal Industries Ltd. (CI), and (ix) CI is the controlling shareholder of CBI. Each of the Reporting Persons (other
than, (x) solely with respect to the securities held directly by CBI, CBI, (y) solely with respect to the securities held directly by Bio Medical, Bio Medical and (z) solely with respect to the securities held directly by AIB, AIB),
and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of the securities held directly by CBI, Bio Medical and AIB.

(c) The following transactions in the Issuers securities have been effected by Reporting Persons within the 60 days prior to this
filing:

On May 21, 2020, AIB purchased 1,111,111 Ordinary Shares at $4.50 per share from the underwriters in the Issuers
public offering of Ordinary Shares pursuant to the Issuers prospectus filed with the SEC by the Issuer pursuant to Rule 424(b)(5) on May 18, 2020.

(d) Not applicable.

(e) Not
applicable.

Item 7

Materials to Be Filed as Exhibits

Exhibit

Description

99.8

Joint Filing Agreement, dated as of May 22, 2020.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.

Date: May 22, 2020

AI GAMIDA HOLDINGS LLC

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive Vice President

ACCESS INDUSTRIES HOLDINGS LLC

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive Vice President

ACCESS INDUSTRIES MANAGEMENT, LLC

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive Vice President

ACCESS INDUSTRIES, LLC

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive Vice President

CLAL BIOTECHNOLOGY INDUSTRIES LTD.

/s/ Ofer Gonen

Name: Ofer Gonen

Title: Chief Executive
Officer

/s/ Assaf Segal

Name: Assaf Segal

Title: Chief
Financial Officer

BIO MEDICAL INVESTMENT (1997) LTD.

/s/ Ofer Gonen

Name: Ofer Gonen

Title: Director

/s/ Assaf Segal

Name: Assaf Segal

Title:
Director

AI BIOTECHNOLOGY LLC

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive Vice President

*

Name: Len Blavatnik

*

The undersigned, by signing his name hereto, executes this Amendment No. 2 to Schedule 13D pursuant to the
Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.

By:

/s/ Alejandro Moreno

Name: Alejandro Moreno

Attorney-in-Fact

EX-99.8
2
d930948dex998.htm
EX-99.8
EX-99.8

Exhibit 99.8

Joint Filing Agreement

The undersigned hereby agree that they are filing this statement jointly pursuant to Rule 13d-1(k)(1).
Each of them is responsible for the timely filing of such Schedule 13D and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the
completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate.

In accordance with Rule 13d-1(k)(1) promulgated under the Securities and Exchange Act of 1934, as
amended, the undersigned hereby agree to the joint filing with each other on behalf of each of them of such a statement on Schedule 13D (and any amendments thereto) with respect to the Ordinary Shares, par value NIS 0.01 per share, beneficially
owned by each of them, of Gamida Cell Ltd., a Private, Limited Liability Company, Registered In Israel. This Joint Filing Agreement shall be included as an exhibit to such Schedule 13D.

[Signature Page Follows]

IN WITNESS WHEREOF, the undersigned hereby execute this Joint Filing Agreement as of the 22nd day of May, 2020.

AI Gamida HOLDINGS LLC

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive
Vice President

ACCESS INDUSTRIES HOLDINGS LLC

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive
Vice President

ACCESS INDUSTRIES MANAGEMENT, LLC

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive
Vice President

ACCESS INDUSTRIES, LLC

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive
Vice President

CLAL BIOTECHNOLOGY INDUSTRIES LTD.

/s/ Ofer Gonen

Name: Ofer Gonen

Title: Chief Executive Officer

/s/ Assaf Segal

Name: Assaf Segal

Title: Chief Financial Officer

BIO MEDICAL INVESTMENT (1997) LTD.

/s/ Ofer Gonen

Name: Ofer Gonen

Title: Director

/s/ Assaf Segal

Name: Assaf Segal

Title: Director

AI BIOTECHNOLOGY LLC

By: Access Industries Management, LLC, Its Manager

/s/ Alejandro Moreno

Name: Alejandro Moreno

Title: Executive Vice President

*

Name: Len Blavatnik

*

The undersigned, by signing his name hereto, executes this Joint Filing Agreement pursuant to the Limited Power
of Attorney executed on behalf of Mr. Blavatnik and filed herewith.